POSTER SESSION III
Tuesday, March 1, 2011 — 9:30 AM - 12:00 Noon
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
26
Hydromark: A Breast Biopsy Site Marker That Elicits a Deceiving Tissue Response, Difficult To Identify as Biopsy Site on Subsequent Excision.
(149)
M Em, P Kane, C Bernstein, R Palermo, C Tornos - Stony Brook University Medical Center, NY
Number of Surgical Excisions Needed To Achieve Pathologically Negative Margins and Ultimate Total Mastectomy (TM) Rates for Invasive Mammary Carcinoma (IMC) and DCIS in a Nationally Accredited Breast Center.
(171)
S Hu, R Jimenez, A Ricci, Jr - Hartford Hospital, CT; Hartford Hospital
Synchronous/Mixed Ductal and Lobular Carcinomas of the Breast: Further Support of the Precursor Nature of Lobular Neoplasia and Its Marker Status for Low Grade Breast Carcinogenesis.
(111)
FI Boulos, FA Fedda, S Ayanian, G Zaatari - American University of Beirut Medical Center, Lebanon
Pathologic Evaluation of Nipple-Areolar Complex Sparing Mastectomy Specimens.
(114)
R Burch-Smith, G Babiera, R Fearmonti, J Wagner, S Krishnamurthy - The University of Texas MD Anderson Cancer Center, Houston
Histopathological Analysis of Nipple Areola Complex Involvement by Breast Carcinoma in 787 Consecutive Therapeutic Mastectomy Specimens from a Single Institution.
(276)
J Wang, X Xiao, J Wang, H Chen, L Baxter, K Skinner, D Hicks, P Tang - Univeristy of Rochester Medical Center, NY; RTI Health Solution, Research Triangle Park, NC
The Pre-Operative Diagnosis Rate as a Quality Measure in Breast Cancer Diagnosis . Current Indications for Surgical Biopsy.
(151)
G Farshid, S Waksmundzki, A Walker, P Downey, S Pieterse, G Gill - BreastScreen SA, Wayville, SA, Australia
Microcalcifications of the Breast: A Mammographic-Histologic Correlation Study Utilizing a Newly Designed Path/Rad Tissue Tray.
(250)
G Schafer, M Redick, M Inciradi, W Smith, F Fan, O Tawfik - Kansas Univ Med Ctr, KS
Histologic Spectrum of Breast Imaging Reporting and Data System-4 (BIRADS- 4) Category Lesions . A Retrospective Study of 2015 Cases.
(123)
DA Chitale, A Stark, RJ Zarbo, D Nathanson, M Burke, N Tang, F Fernandez-Madrid - Henry Ford Hospital, Detroit, MI; Henry Ford Hospital, Detroit; Wayne State Univ., Detroit; Karmanos Comprehensive Cancer Institute, Detroit
Tumor Sampling Using Tissue Microarray Can Alter the Ki-67 Proliferation Index and Cause Misclassification of Breast Tumors.
(120)
C Chisholm, C Yau, C Ruud, VO Speights - Scott & White Memorial Hospital, Temple, TX
The Change in Breast Cancer Survival Rates after the Histological Grade and Estrogen Receptor Status Are Fully Integrated into an Expanded TNM.
(164)
DE Henson, AM Schwartz, D Chen, LE Kostun, S Cheng - The George Washington University, Washington, DC; USUHS, Bethesda, MD
Impact of Additional Magnetic Resonance Imaging (MRI)-Guided Biopsies in Management of Breast Cancer Patients Initially Diagnosed by Non-MRI (Ultrasound/Stereotactic) Modalities.
(124)
M Chivukula, JM Lloyd, D Dabbs - UPMC, Pittsburgh, PA
Pathologic Response and Tumor Thickness at Tumor-Normal Interface (TNI): Potential Prognostic Factors of Disease-Free Survival (DFS) in Liver Metastases of Breast Cancer (LMBC).
(298)
J Zhou, D Rosen, A Brouquet, D Abbott, EM Loyer, F Meric-Bernstam, HM Kuerer, SA Curley, EK Abdalla, KK Hunt, J-N Vauthey, A Sahin, D Maru - The University of Texas M.D.Anderson Cancer Center, Houston
High Mitotic Counts after Neoadjuvant Chemotherapy (NAC) Provide Complementary Prognostic Information to Residual Cancer Burden.
(180)
D Janice, S Lesley, S Nella, L Olivier, S Joseph, F Susan - Montefiore Medical Center (MMC) and the Albert Einstein College of Medicine (AECOM), Bronx, NY; MMC & AECOM, Bronx, NY
The Clinicopathological Predictive Factors of a Therapeutic Effect with Preoperative Neoadjuvant Chemotherapy for Locally Advanced Breast Cancers.
(189)
T Kawasaki, T Kondo, H Yamauchi, T Nakazawa, T Yamane, K Mochizuki, O Takahashi, H Yagata, H Tsunoda, S Nakamura, T Maruyama, A Inoue, M Inoue, S Inoue, K Kono, H Fujii, R Katoh - University of Yamanashi, Japan; St. Luke's International Hospital, Tokyo, Japan
Histopathological Variables on a Scale to Best Refine Prognosis in Breast Cancer Patients.
(119)
I Castellano, S Beatrice, C Marchio', L Chiusa, E Allia, A Vandone, R Arisio, A Durando, M Donadio, A Sapino - University of Turin, Italy; Ospedale San Giovanni Battista, Molinette, Turin, Italy; Sant'Anna Hospital, Turin, Italy
The Histopathologic Findings of Magnetic Resonance Imaging Enhancement of Breast Lesions with Histologically Mass-Negative Lesion: A Single Institution Experience.
(219)
L Monhollen, P Kumar, R Chandrasekhar, G Wilding, T Khoury - Roswell Park Cancer Institute, Buffalo, NY
HER2/Neu Genetic Heterogeneity (GH) in Breast Cancer as Defined by CAP Guidelines Correlates with Negative Prognostic Factors.
(252)
H Shafi, M Schmidt, S Bose - Cedars-Sinai Medical Center, Los Angeles
Prospective Study of HER2 Status in 1386 Invasive Breast Carcinomas. The Impact of the ASCO/CAP 2007 Guidelines.
(273)
M Verdu, M Gonzalez, R Roman, N Rodon, C Pubill, B Martinez, M Gorriz, B Garcia-Pelaez, M Calvo, X Puig - BIOPAT, Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; Hospital de Barcelona, SCIAS, Grup Assistencia, Spain; Histopat Laboratoris, Barcelona, Spain; Universitat Barcelona, Spain
ER IHC Testing in Accordance with Guidelines Established the American Society of Clinical Oncology (ASCO) and by the College of American Pathologists (CAP).
(234)
T Phillips, A Strickland, S Webster, R Welcher - Dako North America, Inc., Carpinteria, CA
Testing the Limits: Reevaluation of the Upper Limit of Formalin Fixation Time Recommended in the ASCO/CAP HER2 Testing Guidelines.
(237)
S Redfield, D Bell, L Rezeanu, A Shaye Brown - The University of Mississippi Medical Center, Jackson
Discordance of Estrogen Receptor (ER), Progesterone Receptor (PR) and Her-2/Neu Expression between Primary Breast Carcinoma and Brain Metastasis.
(170)
S Hooda, G Carter, M Chivukula - UPMC, Pittsburgh, PA
HER2 Testing: The Equivocal Category by Immunohistochemistry Should Be Expanded To Include Cases with Any 2+ Staining and Cases with 3+ Staining in <70% Instead of <30% of Tumor Cells To Have High Concordance Rate with FISH.
(192)
T Khoury, D Tan, W Bshara - Roswell Park Cancer Center, Buffalo; MD anderson Medical Center, Houston
HER2 Testing on Breast Carcinoma Metastases to Bone by Fluorescence In Situ Hybridization: A Study of 28 Cases with an Emphasis on Preanalytic Factors.
(143)
BC Dickson, M Wood, J Mazurkiewicz, MC Chang - Mount Sinai Hosp, Toronto, ON, Canada; Univ of Toronto, ON, Canada
Can Conventional Histopathologic Prognostic Parameters of Invasive Breast Carcinoma Predict the Oncotype DX. Recurrence Score.
(110)
S Bose, AASR Mannan, T Rathgeb - Cedars-Sinai Medical Center, Los Angeles
Expression Level of Estrogen Receptor Determined by PCR Quantification of mRNA from Whole Slide Formalin-Fixed, Paraffin-Embedded Breast Cancer Tissue Sections Correlates with Semiquantitative Immunohistochemical Level and Biochemical Measurements.
(268)
T Tramm, G Hennig, J Alsner, FB Soerensen, J Overgaard - Aarhus University Hospital, Denmark; Siemens Healthcare Diagnostics Holding GmbH, Eschborn, Germany; Vejle Hospital, Denmark
A Nomogram To Predict Oncotype DX Recurrence Scores for ER Positive Breast Cancer Based on Routine Histopathologic Characteristics.
(94)
G Acs, K Turaga, NN Esposito, C Laronga - Ruffolo Hooper & Associates, Tampa, FL; Moffitt Cancer Center, Tampa, FL; University of South Florida College of Medicine, Tampa; Medical College of Wisconsin, Milwaukee
Comparison of the ASCO/CAP and the Allred Scoring/Interpretation Methods in Determination of Estrogen Receptor (ER) and Progesterone Receptor (PgR) Immunoreactivity Using an Immunohistochemical (IHC) Assay.
(283)
R Welcher, T Phillips, D Chenoweth - Dako NA, Carpinteria, CA
Reevaluation of Expression of Estrogen Receptor (ER), Progesterone Receptor (PR), GCDFP-15 and Mammaglobin in Carcinomas from Various Organs.
(202)
H Liu, J Shi, JW Prichard, SC Meschter, F Lin - Geisinger Medical Center, Danville, PA
SP3, an Alternative to HercepTest in Determining HER-2/Neu (H2N) Status in Breast Cancer Patients with Significant Cost Savings.
(137)
TM D'Alfonso, Y-F Liu, S Monni, SJ Shin - Weill Cornell Medical College, New York
button next to any title to add to Itinerary Planner...
Add
